Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20917257 | 0.87 | MAPK1 (0.48) | MAPK1MAPK3MKNK1CHEK1CLK2 | |
| SCHEMBL22299689 | 0.85 | MAPK1 (0.42) | MAPK1MAPK3MKNK1CHEK1BRAF | |
| SCHEMBL22299502 | 0.83 | MAPK1 (0.48) | MAPK1MAPK3MKNK1CHEK1CLK2 | |
| SCHEMBL22299507 | 0.81 | MAPK1 (0.45) | MAPK1MAPK3MKNK1CHEK1BRAF | |
| SCHEMBL30554359 | 0.80 | MAPK1 (0.64) | MAPK1MAPK3DYRK1A | |
| SCHEMBL20931716 | 0.80 | MAPK1 (0.46) | MAPK1MAPK3MKNK1CHEK1BRAF | |
| SCHEMBL20931373 | 0.80 | MAPK1 (0.64) | MAPK1MAPK3DYRK1A | |
| SCHEMBL20931672 | 0.79 | MAPK1 (0.55) | MAPK1MAPK3MKNK1 | |
| SCHEMBL28333310 | 0.79 | PIN1 (0.46) | MAPK1MAPK3MKNK1CHEK1 | |
| SCHEMBL20931576 | 0.79 | MAPK1 (0.66) | MAPK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | MAPK1 1/4885MAPK3 14/4885MKNK1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.